Clinical Trial Search

Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001

Primary: Heart Rate Control — 8; 4 Participants

Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants

Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001

Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants

Primary: Number of Days on Anticoagulation — 24.9 days

Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001

Primary: Inhibition of Idiopathic Ventricular Tachycardia

Primary: Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism…

Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76

Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016

Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants

Primary: Time From Randomization to First Documented AF Recurrence. — 51.0; NA; 117.0; 58.0 Days

Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms

Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants

Primary: The Incidence of Early Onset Primary Adverse Events — 5.5 percentage of participants

Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001

Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants

Primary: Patient Reported Quality of Life (SF-36) — 29.7; 31.9 score on a scale

Primary: Percent of Patients Reaching Target HR<100bpm Within 30 Minutes — 46.4; 95.8 percentage of participants — p=.0001

Primary: Premature Discontinuation of Study or Study Drug Due to Any Reason — 4; 6; 3 Participants

Primary: Mean Difference in Systolic Blood Pressure — -11.7500; -19.5385 mmHg

Primary: Freedom From Procedure-related Serious Adverse Events (SAEs) Within 7-10 Days of the Procedure — 92.7; 88.9 % of participants — p=0.2179

Primary: Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) — 1.3; 1.6; 1.4; 2.3 Percentage of Participants

Primary: Pivotal Main Phase Modified Intent-To-Treat (mITT) Analysis Set: Number of Participants With Primary Adverse Events (PAEs) — 8 Participants

Primary: Proportion of Patients With Treatment-induced Conversion of Atrial Fibrillation to Sinus Rhythm — 29; 7 participants

Primary: All Hospital Episodes (Emergency Room or Patient Request for OPD) Related to Treatment for Atrial Arrhythmia — 19; 76; 23 Participants — p=<0.0001

Primary: Conversion to Sinus Rhythm — 4; 4; 11; 13 participants

Primary: Atrial Fibrillation Burden (AFB) at Baseline — 12.7; 10.8; 11.6; 11.7 Percentage of total recording time

Primary: Subjects Achieving Normal Sinus Rhythm (NSR) in Patients With Paroxysmal AF — 0; 2; 0; 0 Participants